HIV fusion and its inhibition

Antiviral Research

Volumn 50, Issue 2, 2001, Pages 95-115

  Labranche, Celia C ^a   Galasso, George ^b   Moore, John P ^c   Bolognesi, Dani P ^d   Hirsch, Martin S ^e   Hammer, Scott M ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b The Macrae Group   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Trimeris Inc   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ADS J1; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; REVIEW; SALVAGE THERAPY; TOXICITY; VIROGENESIS; VIRUS ADSORPTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 IMMUNOADHESINS; HETEROCYCLIC COMPOUNDS; HIV; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; MEMBRANE FUSION; PEPTIDE FRAGMENTS; RECEPTORS, HIV;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0035036358     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00130-9     Document Type: Review

References (127)

1. Abebe A., Demissie D., Goudsmit J., Brouwer M., Kuiken C.L., Pollakis G., Schuitemaker H., Fontanet A.L., Rinke de Wit T.F. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Aids. 13:(11):1999;1305-1311.
2. Allaway G.P., Davis-Bruno K.L., Beaudry G.A., Garcia E.B., Wong E.L., Ryder A.M., Hasel K.W., Gauduin M.C., Koup R.A., McDougal J.S., et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses. 11:(5):1995;533-539.
3. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA. 96:(10):1999;5698-5703.
4. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:1999;657-700.
5. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Maddon P.J., Olson W.C., Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:(2):2000;627-643.
6. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., Fenyo E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:(10):1997;7478-7487.
7. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3:(1):1997;42-47.
8. Borsetti A., Parolin C., Ridolfi B., Sernicola L., Geraci A., Ensoli B., Titti F. CD4-independent infection of two CD4(-)/CCR5(-)/CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses. J. Virol. 74:(14):2000;6689-6694.
9. Bosch M.L., Earl P.L., Fargnoli K., Picciafuoco S., Giombini F., Wong-Staal F., Franchini G. Identification of the fusion peptide of primate immunodeficiency viruses. Science. 244:(4905):1989;694-697.
10. Brighty D.W., Rosenberg M., Chen I.S., Ivey-Hoyle M. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc. Natl. Acad. Sci. USA. 88:(17):1991;7802-7805.
11. Bullough P.A., Hughson M., Skehel J.J., Wiley D.C. Structure of influenza haemagglutinin at the pH of membrane fusion. J. Virol. 371:1994;37-43.
12. Cao J., Bergeron L., Helseth E., Thali M., Repke H., Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67:(5):1993;2747-2755.
13. Chabot D.J., Zhang P.F., Quinnan G.V., Broder C.C. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J. Virol. 73:(8):1999;6598-6609.
14. Chan D., Fass D., Berger J., Kim P. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
15. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell. 93:(5):1998;681-684.
16. Chou T.C., Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115:(1):1981;207-216.
17. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P. Identification of RANTES, MIP-1a, and MIP-1B as the major HIV suppressive factors produced by CD8+ T cells. Science. 270:1995;1811-1815.
18. Comar M., Marzio G., D'Agaro P., Giacca M. Quantitative dynamics of HIV type 1 expression. AIDS Res. Hum. Retroviruses. 12:(2):1996;117-126.
19. Connor R.I., Sheridan K.E., Ceradini D., Choe S., Landau N.R. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:(4):1997;621-628.
20. Daar E.S., Li X.L., Moudgil T., Ho D.D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA. 87:(17):1990;6574-6578.
21. Datema R., Rabin L., Hincenbergs M., Moreno M.B., Warren S., Linquist V., Rosenwirth B., Seifert J., McCune J.M. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob. Agents Chemother. 40:(3):1996;750-754.
22. De Clercq E. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev. Med. Virol. 10:(4):2000;255-277.
23. Debnath A.K., Radigan L., Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 42:(17):1999;3203-3209.
24. Doms R.W. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology. 276:(2):2000;229-237.
25. Doms R.W., Moore J.P. HIV-1 membrane fusion. Targets of opportunity. J. Cell. Biol. 151:(2):2000;F9-F14.
26. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., Moore J.P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:(1):1998;72-77.
27. Doranz B.J., Grovit-Ferbas K., Sharron M.P., Mao S.H., Goetz M.B., Daar E.S., Doms R.W., O'Brien W.A. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186:(8):1997;1395-1400.
28. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA. 97:(10):2000;5639-5644.
29. D'Souza M.P., Cairns J.S., Plaeger S.F. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA. 284:(2):2000;215-222.
30. Earl P.L., Doms R.W., Moss B. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA. 87:(2):1990;648-652.
31. Edinger A.L., Ahuja M., Sung T., Baxter K.C., Haggarty B., Doms R.W., Hoxie J.A. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein. J. Virol. 74:(17):2000;7922-7935.
32. Edinger A.L., Clements J.E., Doms R.W. Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Virology. 260:(2):1999;211-221.
33. Edinger A.L., Mankowski J.L., Doranz B.J., Margulies B.J., Lee B., Rucker J., Sharron M., Hoffman T.L., Berson J.F., Zink M.C., Hirsch V.M., Clements J.E., Doms R.W. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc. Natl. Acad. Sci. USA. 94:(26):1997;14742-14747.
34. Este J.A., Cabrera C., Blanco J., Gutierrez A., Bridger G., Henson G., Clotet B., Schols D., De Clercq E. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J. Virol. 73:(7):1999;5577-5585.
35. Furuta R.A., Wild C.T., Weng Y., Weiss C.D. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5:(4):1998;276-279. (erratum: 5 (7) (1998) 612).
36. Gabuzda D., Wang J. Chemokine receptors and virus entry in the central nervous system. J. Neurovirol. 5:(6):1999;643-658.
37. Gallaher W.R. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell. 50:1987;327-328.
38. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., Cornelissen I.L., Nottet H.S., KewalRamani V.N., Littman D.R., Figdor C.G., van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells (see comments). Cell. 100:(5):2000;587-597.
39. Havlir D.V., Tierney C., Friedland G.H., Pollard R.B., Smeaton L., Sommadossi J.P., Fox L., Kessler H., Fife K.H., Richman D.D. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182:(1):2000;321-325.
40. Hill C.M., Kwon D., Jones M., Davis C.B., Marmon S., Daugherty B.L., DeMartino J.A., Springer M.S., Unutmaz D., Littman D.R. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology. 248:(2):1998;357-371.
41. Hoffman T.L., LaBranche C.C., Zhang W., Canziani G., Robinson J., Chaiken I., Hoxie J.A., Doms R.W. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. USA. 96:(11):1999;6359-6364.
42. Ivey-Hoyle M., Culp J.S., Chaikin M.A., Hellmig B.D., Matthews T.J., Sweet R.W., Rosenberg M. Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc. Natl. Acad. Sci. USA. 88:(2):1991;512-516.
43. Jacobson J.M., Lowy I., Fletcher C.V., O'Neill T.J., Tran D.N., Ketas T.J., Trkola A., Klotman M.E., Maddon P.J., Olson W.C., Israel R.J. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182:(1):2000;326-329.
44. Ji H., Bracken C., Lu M. Buried polar interactions and conformational stability in the simian immunodeficiency virus (SIV) gp41 core. Biochemistry. 39:(4):2000;676-685.
45. Ji H., Shu W., Burling F.T., Jiang S., Lu M. Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J. Virol. 73:(10):1999;8578-8586.
46. Jiang S., Debnath A.K. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem. Biophys. Res. Commun. 270:(1):2000;153-157.
47. Jiang S., Lin K., Zhang L., Debnath A.K. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Meth. 80:(1):1999;85-96.
48. Kaufmann G.R., Cunningham P., Kelleher A.D., Zaunders J., Carr A., Vizzard J., Law M., Cooper D.A. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J. Infect. Dis. 178:(6):1998;1812-1815.
49. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry (see comments). Nat. Med. 4:(11):1998;1302-1307.
50. Kowalski M., Potz J., Basiripour L., Dorfman T., Goh W.C., Terwillinger E., Dayton A., Rosen C., Haseltine W., Sodroski J. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science. 237:1987;1351-1355.
51. Kuhmann S.E., Platt E.J., Kozak S.L., Kabat D. Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses. J. Virol. 71:(11):1997;8642-8656.
52. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody (see comments). Nature. 393:(6686):1998;648-659.
53. LaBranche C.C., Sauter M.M., Haggarty B.S., Vance P.J., Romano J., Hart T.K., Bugelski P.J., Marsh M., Hoxie J.A. A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J. Virol. 69:(9):1995;5217-5227.
54. Labrosse B., Brelot A., Heveker N., Sol N., Schols D., De Clercq E., Alizon M. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J. Virol. 72:(8):1998;6381-6388.
55. Lapham C.K., Zaitseva M.B., Lee S., Romanstseva T., Golding H. Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nat. Med. 5:(3):1999;303-308. (erratum: 5(5) (1999) 590).
56. Lee B., Sharron M., Blanpain C., Doranz B.J., Vakili J., Setoh P., Berg E., Liu G., Guy H.R., Durell S.R., Parmentier M., Chang C.N., Price K., Tsang M., Doms R.W. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274:(14):1999;9617-9626.
57. Li S., Juarez J., Alali M., Dwyer D., Collman R., Cunningham A., Naif H.M. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J. Virol. 73:(12):1999;9741-9755.
58. Liu H., Soda Y., Shimizu N., Haraguchi Y., Jinno A., Takeuchi Y., Hoshino H. CD4-Dependent and CD4-independent utilization of coreceptors by human immunodeficiency viruses type 2 and simian immunodeficiency viruses. Virology. 278:(1):2000;276-288.
59. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:1996;367-377.
60. Mack M., Luckow B., Nelson P.J., Cihak J., Simmons G., Clapham P.R., Signoret N., Marsh M., Stangassinger M., Borlat F., Wells T.N., Schlondorff D., Proudfoot A.E. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187:(8):1998;1215-1224.
61. Matsushita S. Current status and future issues in the treatment of HIV-1 infection. Int. J. Hematol. 72:(1):2000;20-27.
62. McIntosh K., Chanock R.M. Fields B.N., Knipe D.M. Virology. 1990;1045-1072 Raven Press, New York.
63. McKeating J.A., Willey R.L. Structure and function of the HIV envelope. Aids. 3:(Suppl. 1):1989;S35-S41.
64. Melikyan G.B., Markosyan R.M., Hemmati H., Delmedico M.K., Lambert D.M., Cohen F.S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell. Biol. 151:(2):2000;413-424.
65. Merrill D.P., Moonis M., Chou T.C., Hirsch M.S. Lamivudine (3TC) or stavudine (d4T) in two and three-drug combinations against HIV-1 replication in vitro. J. Infect. Dis. 173:1996;355-364.
66. Mondor I., Ugolini S., Sattentau Q.J. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 72:(5):1998;3623-3634.
67. Moore J.P., Stevenson M. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell. Biol. 1:2000;40-49.
68. Moore J.P., Trkola A., Dragic T. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 9:(4):1997;551-562.
69. Mosier D.E., Picchio G.R., Gulizia R.J., Sabbe R., Poignard P., Picard L., Offord R.E., Thompson D.A., Wilken J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73:(5):1999;3544-3550.
70. Murakami T., Zhang T.Y., Koyanagi Y., Tanaka Y., Kim J., Suzuki Y., Minoguchi S., Tamamura H., Waki M., Matsumoto A., Fujii N., Shida H., Hoxie J.A., Peiper S.C., Yamamoto N. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J. Virol. 73:(9):1999;7489-7496.
71. Myszka D.G., Sweet R.W., Hensley P., Brigham-Burke M., Kwong P.D., Hendrickson W.A., Wyatt R., Sodroski J., Doyle M.L. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. USA. 97:(16):2000;9026-9031.
72. O'Brien W.A., Sumner-Smith M., Mao S.H., Sadeghi S., Zhao J.Q., Chen I.S. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Virol. 70:(5):1996;2825-2831.
73. Olson W.C., Rabut G.E., Nagashima K.A., Tran D.N., Anselma D.J., Monard S.P., Segal J.P., Thompson D.A., Kajumo F., Guo Y., Moore J.P., Maddon P.J., Dragic T. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73:(5):1999;4145-4155.
74. Oppermann M., Mack M., Proudfoot A.E., Olbrich H. Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J. Biol. Chem. 274:(13):1999;8875-8885.
75. Pantaleo G., Graziosi C., Fauci A.S. The immunopathogenesis of human immunodeficiency virus infection. New Engl. J. Med. 328:1993;327-335.
76. Peeters M., Vincent R., Perret J.L., Lasky M., Patrel D., Liegeois F., Courgnaud V., Seng R., Matton T., Molinier S., Delaporte E. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:(2):1999;115-121.
77. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:(5255):1996;1582-1586.
78. Poeschla E.M., Looney D.J. CXCR4 is required by a nonprimate lentivirus: heterologous expression of feline immunodeficiency virus in human, rodent, and feline cells. J. Virol. 72:(8):1998;6858-6866.
79. Proudfoot A.E., Power C.A., Hoogewerf A.J., Montjovent M.O., Borlat F., Offord R.E., Wells T.N. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271:(5):1996;2599-2603.
80. Reeves J.D., Hibbitts S., Simmons G., McKnight A., Azevedo-Pereira J.M., Moniz-Pereira J., Clapham P.R. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4- negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J. Virol. 73:(9):1999;7795-7804.
81. Reimann K.A., Tenner-Racz K., Racz P., Montefiori D.C., Yasutomi Y., Lin W., Ransil B.J., Letvin N.L. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J. Virol. 68:(4):1994;2362-2370.
82. Richman D.D., Bozzette S.A. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169:(5):1994;968-974.
83. Rimsky L.T., Shugars D.C., Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:1998;986-993.
84. Rizzuto C., Sodroski J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses. 16:(8):2000;741-749.
85. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding (see comments). Science. 280:(5371):1998;1949-1953.
86. de Roda Husman A., van Rij R.P., Blaak H., Broersen S., Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J. Infect. Dis. 180:1999;1106-1115.
87. Root M.J., Kay M.S., Kim P.S. Protein design of an HIV-1 entry inhibitor. Science. 291:2001;884-888.
88. Rowell J.F., Stanhope P.E., Siliciano R.F. Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J. Immunol. 155:(1):1995;473-488.
89. Sabbe R., Picchio G.R., Pastore C., Chaloin O., Hartley O., Offord R., Mosier D.E. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J. Virol. 75:(2):2001;661-671.
90. Salzwedel K., Smith E.D., Dey B., Berger E.A. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 env function: soluble CD4 activates env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J. Virol. 74:(1):2000;326-333.
91. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene (see comments). Nature. 382:(6593):1996;722-725.
92. Sattentau Q.J., Moore J.P. The role of CD4 in HIV binding and entry (review). Philos. Trans. R. Soc. Lond. Biol. 342:(1299):1993;59-66.
93. Sauter M.M., Pelchen-Matthews A., Bron R., Marsh M., LaBranche C.C., Vance P.J., Romano J., Haggarty B.S., Hart T.K., Lee W.M., Hoxie J.A. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J. Cell. Biol. 132:(5):1996;795-811.
94. Schacker T., Collier A.C., Coombs R., Unadkat J.D., Fox I., Alam J., Wang J.P., Eggert E., Corey L. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9:(2):1995;145-152.
95. Schols D., Este J.A., Henson G., De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. 35:(3):1997;147-156.
96. Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., de Goede R.E., van Steenwijk R.P., Lange J.M., Schattenkerk J.K., Miedema F., Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66:(3):1992;1354-1360.
97. Shankarappa R., Margolick J.B., Gange S.J., Rodrigo A.G., Upchurch D., Farzadegan H., Gupta P., Rinaldo C.R., Learn G.H., He X., Huang X.L., Mullins J.I. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73:(12):1999;10489-10502.
98. Shearer W.T., Israel R.J., Starr S., Fletcher C.V., Wara D., Rathore M., Church J., DeVille J., Fenton T., Graham B., Samson P., Staprans S., McNamara J., Moye J., Maddon P.J., Olson W.C. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study (in process citation). J. Infect. Dis. 182:(6):2000;1774-1779.
99. Simmons G., Clapham P.R., Picard L., Offord R.E., Rosenkilde M.M., Schwartz T.W., Buser R., Wells T.N.C., Proudfoot A.E. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science. 276:(5310):1997;276-279.
100. Skehel J.J., Wiley D.C. Coiled coils in both intracellular vesicle and viral membrane fusion. Cell. 95:(7):1998;871-874.
101. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69:2000;531-569.
102. Stamatatos L., Cheng-Mayer C. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69:(10):1995;6191-6198.
103. Stamatatos L., Lim M., Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses. 16:(10):2000;981-994.
104. Staropoli I., Chanel C., Girard M., Altmeyer R. Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate. J. Biol. Chem. 275:(45):2000;35137-35145.
105. Stott E.J., Schild G.C. Strategies for AIDS vaccines. J. Antimicrob. Chemother. 37:(11):1996;185-198.
106. Sugiura W., Broder C.C., Moss B., Earl P.L. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Virology. 254:(2):1999;257-267.
107. Sullivan N., Sun Y., Sattentau Q., Thali M., Wu D., Denisova G., Gershoni J., Robinson J., Moore J., Sodroski J. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72:(6):1998;4694-4703.
108. Tamamura H., Imai M., Ishihara T., Masuda M., Funakoshi H., Oyake H., Murakami T., Arakaki R., Nakashima H., Otaka A., Ibuka T., Waki M., Matsumoto A., Yamamoto N., Fujii N. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg. Med. Chem. 6:(7):1998;1033-1041.
109. Tremblay C.L., Kollmann C., Giguel F., Chou T.C., Hirsch M.S. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immune Defic. Syndr. 25:(2):2000;99-102.
110. Trkola A., Ketas T.J., Nagashima K.A., Zhao L., Cilliers T., Morris L., Moore J.P., Maddon P.J., Olson W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75:(2):2001;579-588.
111. Tscherning C., Alaeus A., Fredriksson R., Bjorndal A., Deng H., Littman D.R., Fenyo E.M., Albert J. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology. 241:(2):1998;181-188.
112. Ullrich R., Schmidt W., Zippel T., Schneider T., Zeitz M., Riecken E.O. Mucosal HIV infection. Pathobiology. 66:(3-4):1998;145-150.
113. Vila-Coro A.J., Mellado M., Martin de Ana A., Martinez A.C., Rodriguez-Frade J.M. Characterization of RANTES- and aminooxypentane-RANTES-triggered desensitization signals reveals differences in recruitment of the G protein-coupled receptor complex. J. Immunol. 163:(6):1999;3037-3044.
114. White J.M. Membrane fusion: the influenza paradigm. Cold Spring. Harb. Symp. Quant. Biol. 60:1995;581-588.
115. WHO, 2000. AIDS Epidemic Update, December. http://www.unaids.org/wac/2000 , ed. Joint United Nations Programme on HIV/AIDS (UNAIDS).
116. Wild C., Dubay J., Greenwell T., Baird T., Oas T.G., McDanal C., Hunter E., Matthews T. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA. 91:1994;12676-12680.
117. Wild C., Greenwell T., Shugars D., Rimsky-Clarke L., Matthews T. The inhibitory activity of a HIV-1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses. 11:1995;323-325.
118. Willett B.J., Adema K., Heveker N., Brelot A., Picard L., Alizon M., Turner J.D., Hoxie J.A., Peiper S., Neil J.C., Hosie M.J. The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus. J. Virol. 72:(8):1998;6475-6481. (erratum: 72 (10) (1998) 8460).
119. Wyatt R., Desjardin E., Olshevsky U., Nixon C., Binley J., Olshevsky V., Sodroski J. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J. Virol. 71:(12):1997;9722-9731.
120. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:(6686):1998;705-711.
121. Wyatt R., Moore J., Accola M., Desjardin E., Robinson J., Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:(9):1995;5723-5733.
122. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280:(5371):1998;1884-1888.
123. Xiao L., Rudolph D.L., Owen S.M., Spira T.J., Lal R.B. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS. 12:(13):1998;F137-F143.
124. Yang X., Farzan M., Wyatt R., Sodroski J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 74:(12):2000;5716-5725.
125. Young B., Kuritzkes D.R. Viral kinetics: implications for treatment. AIDS. 13:(Suppl. 1):1999;S11-S17.
126. Zhang W., Canziani G., Plugariu C., Wyatt R., Sodroski J., Sweet R., Kwong P., Hendrickson W., Chaiken I. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry. 38:(29):1999;9405-9416.
127. Zhang Y.J., Dragic T., Cao Y., Kostrikis L., Kwon D.S., Littman D.R., KewalRamani V.N., Moore J.P. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72:(11):1998;9337-9344.